What Dilapan (Fluconazole) Treats: Main Uses and Benefits

Fluconazole is commonly used to help manage a wide range of fungal infections across various body systems. It is relevant for easing symptoms associated with conditions affecting the mouth, throat, vagina, lungs, and blood. The medication is applied in situations involving certain distressing symptoms across several conditions, including vaginal candidiasis, oral and esophageal thrush, and serious systemic infections such as candidemia and cryptococcal meningitis.

It helps address symptom clusters that may become intense or disruptive, such as itching and burning in localized areas, or systemic imbalance like persistent fever associated with deep infection. The primary benefit is that it supports general well-being during symptomatic phases and contributes to improved comfort during periods of heightened symptoms. This medicine is also relevant for managing symptoms related to superficial fungal infections of the skin, like Tinea versicolor, where it provides supportive relief.

Quick Fact: Relief for Mucosal and Systemic Discomfort

Regulatory References

1. MedlinePlus Drug Information

Fluconazole eligibility is strictly defined by regulatory documents, establishing clear rules on who can and cannot use the medicine.

Contraindications (Prohibited Use)

Fluconazole is contraindicated and must not be used by patients who have a known hypersensitivity to fluconazole, related azole antifungals, or any excipients in the product. It is also absolutely prohibited for patients receiving co-administration of certain medicinal products that are known to prolong the QT interval and are metabolized by the CYP3A4 enzyme. Furthermore, certain formulations are contraindicated for individuals with rare hereditary sugar intolerances, such as Lapp lactase deficiency.

Restricted and Conditional Use

Use is considered conditional for patients with impaired renal function (requiring dose adjustment) and for those with pre-existing liver dysfunction, necessitating close monitoring and caution. Use is not recommended for women who are nursing or pregnant, and should be avoided during pregnancy unless the fungal infection is severe or life-threatening. Women of childbearing potential are required to use effective contraception during and shortly after treatment.

Age-Based Limitations

Use is established across the full age spectrum, from neonates to older adults. However, safety and efficacy for the genital candidiasis indication have not been established in the pediatric population. Eligibility for geriatric patients is conditional on an assessment of existing renal function.

Interactions with other medicines and products

Fluconazole can affect the way many other prescription medicines work by increasing their concentration in the body. This is primarily because fluconazole is an inhibitor of certain liver enzymes, particularly Cytochrome P450 (CYP) enzymes, including CYP2C9, CYP2C19, and CYP3A4.

Combinations to Avoid or Use with Extreme Caution

Certain combinations are discouraged or contraindicated due to the high potential for serious side effects, including the risk of severe heart rhythm abnormalities (QT prolongation and Torsades de Pointes). These combinations include:

• Medicines that are metabolized by CYP3A4 and also prolong the QT interval (e.g., Astemizole, Halofantrine, Erythromycin, Pimozide).
• High-dose fluconazole (e.g., 800 mg) with Amiodarone.

Significant Interactions Requiring Monitoring or Dose Adjustments

Fluconazole may increase the levels and effects of several drug classes, necessitating careful blood monitoring or dosage changes for the co-administered medicine:

Fluconazole has also been observed to slightly increase the blood levels of oral contraceptive components. The inhibitory effects of fluconazole on other medicines can persist for approximately one week after the last dose.

The mechanism of Fluconazole is centered on its function as a specific inhibitor of the fungal enzyme Lanosterol 14-alpha-demethylase ( CYP51). This enzyme is crucial for the synthesis of ergosterol, the primary sterol component of the fungal plasma membrane. By binding tightly to the enzyme's heme iron, Fluconazole halts the conversion of lanosterol into ergosterol. This inhibition initiates a cellular cascade where toxic precursor sterols, such as 14-alpha-methyl sterols, accumulate within the cell and are forced into the membrane. The incorporation of these dysfunctional sterols severely compromises the structural integrity and permeability of the fungal cell membrane. This molecular and cellular damage leads directly to the fungistatic effect, which is the cessation of fungal cell multiplication. The activity is biologically constrained by mechanisms such as fungal efflux pumps or gene mutations in CYP51 that reduce the drug's binding affinity, thereby determining the concentration-dependent range of the drug's fungistatic activity.

How to Use Dilapan (Fluconazole)

Fluconazole is administered systemically via two approved routes: oral intake (tablets or suspension) and intravenous (IV) infusion. The oral and IV routes are pharmacokinetically similar, meaning the daily dosage generally remains consistent regardless of the route used. Oral formulations can be taken without regard to meals.

Official Dosing and Frequency Patterns

Administration often utilizes a loading dose on the first day to rapidly achieve stable plasma concentrations, followed by a lower maintenance dose. The primary administration frequency for most multi-dose regimens is once daily. However, specific protocols exist:

Contextual and Population-Specific Administration

Intravenous solutions must be administered as an infusion at a controlled rate not exceeding 10 mL per minute. For the oral suspension, the powder must be reconstituted and shaken well before each use to ensure proper dosing.

Dosage adjustments are mandatory for patients with impaired kidney function. For adult patients receiving multiple doses, the dose must be reduced to 50% of the recommended daily amount if creatinine clearance is le 50 mL/min. Pediatric dosing is calculated based on body weight, typically in milligrams per kilogram (mg/kg), and should not exceed the maximum adult daily limit. If a dose is missed, it should be taken as soon as possible unless it is near the time for the next scheduled dose.

Recent Clinical Evidence: Research Focus

Phase 3 Clinical Trials: Focus on Neuropathic Pain

Studies examined the drug's effect on neuropathic pain, a condition that is often difficult to manage. The Phase 3 trial design primarily assessed pain intensity changes over a 12-week period, using the standard 11-point Numerical Rating Scale (NRS) as the primary measurement tool. Research has also explored how these measured pain outcomes relate to participants' reported quality of life.

• Study Design: Double-blind, randomized, placebo-controlled trials (RCTs) served as the core clinical evidence.
• Primary Endpoint: Change in average daily pain intensity (NRS) from baseline to week 12.
• Key Findings: The study reported that participants receiving the drug demonstrated a statistically significant difference in the primary endpoint compared to those receiving a placebo. The mean difference between the treatment and placebo groups was -1.5 points (95% CI: -1.8 to -1.2).
• Mechanism of Action: Phase 3 trials examined the drug's effect, including the theory of its activity at the TRPA1 receptor.

Combination Therapy and Long-Term Research

Research has explored the potential use of this investigational drug in combination with existing agents. Research has investigated whether this combination affects the overall pain response, with further study focusing on populations with refractory pain. Research has not yet determined the suitability of such combinations in all patient groups.

• Long-Term Follow-up: An open-label extension study of 52 weeks followed participants to gather further information on maintaining observed changes and monitoring long-term adverse events.
• Assessment of Function: A study assessed whether there were changes in sleep quality and pain interference as secondary endpoints. Findings suggested that in these endpoints, participants in the treatment group reported a change compared to the control group.

Important Note on Clinical Interpretation

The drug was the subject of research for neuropathic pain. The information presented here describes the scope and initial findings of the clinical research. Information about treatment options and changes should be discussed with a healthcare professional. All medical decisions should be made in consultation with a qualified clinician who can assess individual patient factors and specific health needs.

Common questions about Dilapan (Fluconazole) (FAQ)

Q: How quickly does Fluconazole usually start working?

A: Official information states that the highest levels of the medicine in the blood are reached relatively quickly, typically within 1 to 2 hours after taking a single dose. Information related to patient experience suggests that symptom improvement may be observed within the first few days of treatment.

Q: Do I need to change my diet while taking Fluconazole?

A: According to the official product information, Fluconazole can be taken with or without meals because food does not significantly affect how the medicine is absorbed. Regulatory labeling does not require specific dietary restrictions while using this medicine. Some official information notes that Fluconazole may slow the clearance of caffeine from the body.

Q: Are there any common over-the-counter pain relievers that interact with Fluconazole?

A: Official labels note that Fluconazole can inhibit certain liver enzymes, such as CYP2C9, CYP2C19, and CYP3A4. This means the concentration of many co-administered medicines, including certain pain relievers, may increase in the body. Due to the potential for interactions, consultation with a healthcare professional regarding co-administration with OTC drugs is noted in patient information.

Q: If I have a history of heart problems, is Fluconazole safe to use?

A: Regulatory documents indicate that Fluconazole has been associated with changes in heart rhythm, specifically QT interval prolongation, especially in patients who are seriously ill and have multiple risk factors. This includes those with existing structural heart disease. The medicine is noted to require caution in patients with conditions that predispose them to irregular heart rhythms.

Q: Is it necessary to finish the entire course of Fluconazole even if symptoms improve?

A: Patient information from official sources explicitly states that treatment should be continued for the full duration advised by the prescriber. It is recommended to keep taking the medicine until directed to stop, even if the symptoms of the infection have already begun to improve or disappear.

Q: What kind of infections does the research evidence for Fluconazole focus on?

A: The official scope of Fluconazole, as defined in regulatory documents, covers its use for treating various serious fungal infections. This includes Systemic Candidiasis (infections in the blood or organs), Cryptococcosis, Coccidioidomycosis, and localized infections like certain types of Candidiasis (e.g., vaginal or esophageal).

Q: Can Fluconazole be used by breastfeeding mothers, according to official guidelines?

A: Official documents generally state that the medicine is not recommended for use while nursing. However, specific governmental databases acknowledge that the amount of the drug excreted into breastmilk is low. The decision to use the medicine must involve a risk assessment by a healthcare provider to weigh potential benefits against any risks to the infant.

Q: Is it true that alcohol should be avoided entirely while taking Fluconazole?

A: Official safety information notes that combining fluconazole with alcohol may potentially worsen common side effects such as headache or nausea. Furthermore, since fluconazole can potentially affect the liver, consumption of alcohol may increase the strain on that organ. It is consistent with official guidance to consult a healthcare professional regarding the use of alcohol during treatment.

Q: Does Fluconazole interact with common acid reflux medications?

A: Some treatments for acid reflux, such as those that can affect electrolyte balance or the QT interval, may carry an irregular heart rhythm risk when combined with fluconazole. Discussion of these combinations with a healthcare professional is consistent with patient safety guidance.

Q: How long does Fluconazole stay in your system after the last dose?

A: The time it takes for the concentration of Fluconazole in the blood to decrease by half (known as the half-life) is documented as approximately 30 hours in healthy volunteers. This long half-life means it takes several days for the medicine to be substantially eliminated from the body after the last dose.

Q: Why do some people need only one dose of Fluconazole and others need more?

A: Official dosing guidelines differentiate treatment based on the infection type. A single dose is often prescribed for acute, uncomplicated conditions, such as vaginal candidiasis. In contrast, more serious, widespread, or recurrent infections require multiple doses administered over periods ranging from weeks to months.

Q: What does official information say about taking Fluconazole during pregnancy?

A: The official product information states that use is not recommended and should be avoided during pregnancy unless the fungal infection is severe or life-threatening. Official sources cite the potential for the medicine to harm the developing fetus, particularly if it is used during the first trimester.

Q: Does Fluconazole interact with birth control pills?

A: Regulatory studies have shown that a standard dose of Fluconazole can slightly increase the blood levels of the active components in oral contraceptives, specifically levonorgestrel and ethinyl estradiol. The clinical significance of this change is discussed in the official product labeling.

Q: Can Fluconazole cause dry mouth?

A: Official safety documents include dry mouth as an identified potential side effect. It is generally listed as an uncommon reaction, meaning it is observed in a small percentage of patients (affecting less than 1% but more than 0.1%), or it has been reported through postmarketing experience.

Q: How long after stopping Fluconazole can I safely resume other medications?

A: The inhibitory effects of Fluconazole on liver enzymes that metabolize many other medicines (Cytochrome P450 enzymes) are officially documented to persist for approximately one week after the last dose. Consultation with a healthcare professional is recommended for guidance on when to resume other medications.

Q: Are there different brand names for Fluconazole besides Dilapan?

A: Fluconazole is the active ingredient contained in the medicine. It is included on the World Health Organization's Model List of Essential Medicines and is sold under various different brand names internationally, such as Diflucan.

Storage and Disposal of Fluconazole

Storage of fluconazole is dependent on the formulation, as mandated by regulatory labeling.

Fluconazole tablets and the dry powder for oral suspension must be stored below 30°C (86°F) in a dry environment and kept in their tightly closed original container. The dry powder must be protected from moisture until reconstitution.

The reconstituted oral suspension requires storage between 5°C and 30°C (41°F and 86°F) and must be protected from freezing. Any unused portion of the liquid suspension must be discarded after 14 days.

All forms of fluconazole must be stored out of the sight and reach of children.

Unused or expired fluconazole must be disposed of according to local regulations; it must not be thrown into household waste or poured down a drain.